Profound Medical Corp
TSX:PRN

Watchlist Manager
Profound Medical Corp Logo
Profound Medical Corp
TSX:PRN
Watchlist
Price: 10.61 CAD 0.57% Market Closed
Market Cap: 261.7m CAD
Have any thoughts about
Profound Medical Corp?
Write Note

Profound Medical Corp
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Profound Medical Corp
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Profound Medical Corp
TSX:PRN
Long-Term Debt
$4.4m
CAGR 3-Years
55%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Long-Term Debt
$595k
CAGR 3-Years
-17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Long-Term Debt
CA$8.2m
CAGR 3-Years
-9%
CAGR 5-Years
66%
CAGR 10-Years
12%
Nanalysis Scientific Corp
XTSX:NSCI
Long-Term Debt
CA$14.7m
CAGR 3-Years
64%
CAGR 5-Years
81%
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Long-Term Debt
CA$244.9k
CAGR 3-Years
251%
CAGR 5-Years
18%
CAGR 10-Years
N/A
MedMira Inc
XTSX:MIR
Long-Term Debt
CA$2.6m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
-5%
No Stocks Found

Profound Medical Corp
Glance View

Market Cap
259.8m CAD
Industry
Health Care

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRN Intrinsic Value
5.8 CAD
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Profound Medical Corp's Long-Term Debt?
Long-Term Debt
4.4m USD

Based on the financial report for Jun 30, 2024, Profound Medical Corp's Long-Term Debt amounts to 4.4m USD.

What is Profound Medical Corp's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
-12%

Over the last year, the Long-Term Debt growth was 517%. The average annual Long-Term Debt growth rates for Profound Medical Corp have been 55% over the past three years , -12% over the past five years .

Back to Top